trending Market Intelligence /marketintelligence/en/news-insights/trending/USEVCpN7LKVBNVPUlzLUWQ2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

UCB's psoriasis drug Cimzia meets endpoint in final phase 3 trial


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Climate Credit Analytics: Linking climate scenarios to financial impacts


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

UCB's psoriasis drug Cimzia meets endpoint in final phase 3 trial

UCB SA's psoriasis drug Cimzia met the primary and several secondary endpoints in its third and final phase 3 trial.

The CIMPACT trial confirmed the safety and efficacy findings from the previous phase 3 trials. Patients with moderate-to-severe chronic plaque psoriasis showed 75% or greater disease improvement from baseline when treated with Cimzia, as compared with placebo.

Plaque psoriasis is the most common form of the psoriasis family of skin diseases and appears as raised, red patches covered with a silvery white buildup of dead skin cells.

The drug is being co-developed by UCB and Dermira Inc. as part of an agreement in July 2014. Dermira has exclusive rights to develop Cimzia for psoriasis in the U.S., Canada and the EU, and an exclusive commercial license to market the drug to dermatologists in the U.S. and Canada, subject to regulatory approval.

The companies expect to submit the drug for regulatory approvals in the third quarter of 2017.